ThermoGenesis Receives Health Canada Approval of its PXP System for Automated Processing of Bone Marrow Cells
RANCHO CORDOVA, Calif., Feb. 25, 2019 /PRNewswire/ -- ThermoGenesis Corp, a private corporation owned by Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced that it received Health Canada approval of its PXP® System for point-of-care harvesting of purified mononuclear cells and platelets from blood or bone marrow.
The ThermoGenesis PXP System is a semi-automated, functionally-closed system that harvests a precise volume of cell concentrate from a fixed sample of bone marrow aspirate. PXP can generate a concentration of bone marrow in less than 20 minutes, with consistently high mononuclear cell (MNC) and CD34+ progenitor cell recovery rates and greater than 98% depletion of contaminating RBCs and 80% depletion of granulocytes (GRN). PXP, together with Cesca's CAR-TXpress™ and related X-Series systems, comprise an advanced and clinically differentiated portfolio of cellular processing solutions.
Haihong Zhu, President of ThermoGenesis, stated, "Health Canada's approval of the PXP® System is an important next step in our commercialization efforts. It reinforces our ability to bring new and innovative solutions to clinicians in need of automated cell processing products that can streamline the manufacturing process, particularly for the emerging CAR-T immunotherapy market where high drug cost and low capacity create significant barriers to the application of these therapies."
Ms. Zhu added, "The PXP System addresses many of the shortcomings of currently available systems, most notably, red blood cell contamination in the resulting cell concentrate that is thought to diminish the efficacy of cell based treatments. PXP allows clinicians to rapidly achieve very high stem and progenitor cell recovery rates with negligible RBC and GRN contamination."
About ThermoGenesis
ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has developed an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For additional information, please visit: www.thermogenesis.com.
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. is a market leader in cell processing technologies and autologous cell therapies for regenerative medicine. For more information, visit: www.cescatherapeutics.com.
Company Contact:
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
[email protected]
SOURCE Cesca Therapeutics Inc.
Share this article